Margot Schoenborn

Chief Executive Officer

Margot Schoenborn serves as Chief Executive Officer and a member of the Board of Directors. She is responsible for leading corporate strategy and oversight of all commercial and corporate functions, while partnering with the Company’s leadership team to enable OmniSeq to realize the potential of its genomic testing and next-generation sequencing (NGS) assays in clinical and research settings.

She also serves as the President, General Counsel and Corporate Secretary. Margot has experience in corporate development, capital planning, transactions, capital markets activities, corporate finance, and leadership of multi-functional teams over a nearly 20-year career in healthcare, law enforcement, and commercial litigation.

Prior to being appointed CEO in 2019, Margot was the Company’s Chief Administrative Officer and General Counsel, where she served as advisor to the Chairman, CEO and Board on governance, executive compensation, strategic alliances, and capital planning, including Series B fundraising activities that secured investments from leading global life sciences and technology companies. As CAO, she was responsible for OmniSeq’s finance, managed care, billing, HR, customer service, risk management, compliance and legal functions.

Prior to joining OmniSeq in 2015, Margot was Deputy General Counsel at Roswell Park Comprehensive Cancer Center. Before joining Roswell Park, she led multi-state investigations of healthcare fraud by global life sciences companies as a special assistant attorney general for New York and an assistant U.S. attorney for the Eastern District of New York. She began her career as a commercial litigator with the New York City office of Nixon Peabody, after graduating from the University at Buffalo School of Law and Nazareth College.